Tau pSer396 and pSer404 Define Distinct Epitope Regions Linked to Different Antibody Functions

Hyperphosphorylated tau is a central pathological feature of Alzheimers disease and related tauopathies, and antibodies targeting the pSer396/pSer404 epitope region represent a promising therapeutic strategy. However, direct comparisons of pSer396- and pSer404-selective antibodies and the impact of humanization on their functional properties remain limited. We generated two new monoclonal antibodies (mAbs), 9E (pSer404-specific) and G10 (pSer396-specific), and evaluated them alongside 4E6 (pSer404) and PHF-1 (pSer396) in murine and partially humanized chimeric formats. Antibodies were assessed in mixed cortical cultures using extracellular (PHF + Ab) and intracellular (PHF [->] Ab) paradigms. Efficacy in preventing tau-induced toxicity and seeding differed substantially among antibodies and was variably altered by chimerization, despite identical variable regions. Antibodies targeting pSer404 were more effective than those targeting pSer396, and antibodies that preferentially bound soluble pathological tau species in competition ELISA were consistently more efficacious, whereas neuronal uptake was comparable across variants. To define structural determinants of phospho-epitope recognition, we determined the crystal structures of the Fab regions of 9E, G10, and PHF-1, and additionally solved the co-crystal structure of Fab PHF-1 in complex with a pSer396 tau peptide at 2.55 [A] resolution. The PHF-1 complex reveals a heavy-chain-dominant binding mode in which pSer396 is anchored within an electropositive pocket and Tyr394 adopts a flipped conformation that stabilizes a {beta}-strand-like motif, consistent with a phosphorylation-dependent conformational switch. These findings demonstrate that epitope selectivity, aggregate preference, structural binding mode, and Fc context collectively govern antibody efficacy, and that humanization can substantially alter therapeutic properties.